Door opener for SomnoMed
Scott Power
Morgans
SomnoMed has received approval to begin the commercialisation of the world’s first oral device for Obstructive Sleep Apnea (OSA) with the ability to objectively measure compliance rates and report back to the clinicians. This is a very important step for the efficacy of COAT ™ devices to clinicians/insurers and we believe this ability will act as a door opener to the prescribers and payers alike for mild to moderate sleep apnea. We upgrade our price target to A$3.23 and retain an Add recommendation. Report attached and the link to the blog site is here: (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media.
I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these sectors, which help with identification of key trends and developments.
1 stock mentioned
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment